Merck asks FDA to approve emergency antiviral medication

Merck said Monday it had asked the Food and Drug Administration to approve the emergency use of its experimental antiviral pill for the treatment of mild to moderate Covid-19 in adults.

The U.S. drugmaker’s inquiry came after Phase 3 clinical trial data released October 1 showed the drug – known as molnupiravir – reduced the likelihood of newly diagnosed patients being hospitalized with Covid by about 50% .

The drug works by stopping the virus from multiplying in the body. Unlike Gilead Sciences’ intravenous drug Remdesivir, Merck’s molnupiravir can be taken orally. If approved by U.S. regulators, it would be the first pill to treat Covid, a potentially groundbreaking advance in the fight against the virus, which kills an average of more than 1,600 Americans a day.

“The extraordinary effects of this pandemic require that we deal with unprecedented
Urgency, and that’s exactly what our teams did by filing this application for molnupiravir with the FDA within 10 days of receiving the data, “said Robert Davis, CEO of Merck, in a press release.

The pill could be available to Americans by the end of this year. Merck, which co-developed the drug with Ridgeback Biotherapeutics, said it was actively working with regulatory agencies around the world to file emergency or regulatory applications “in the coming months”.

The company agreed earlier this year to ship approximately 1.7 million molnupiravir courses to the United States if it receives emergency clearance or full approval from the FDA. According to The New York Times, five days of treatment with the drug costs the federal government about $ 700 per patient, one-third the current cost of monoclonal antibodies.

While vaccinations remain the best form of protection against the virus, U.S. officials and health experts hope a pill like Merck’s will prevent the disease from getting worse in those who become infected and preventing trips to hospital.

Pills like Merck’s are considered a kind of “holy grail” for treatments, said Dr. Mike Ryan, Executive Director of the World Health Organization’s Emergency Health Program, at a news conference last week.

Other drug manufacturers are also working on antiviral pills. Pfizer CEO Albert Bourla told CNBC in April that one of Pfizer, who developed BioNTech’s first approved Covid vaccine in the US, could be available by the end of this year.

Leave your vote

0 points
Upvote Downvote

Related Articles

Log In

Forgot password?

Don't have an account? Register

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.